Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.

AUTOR(ES)

Tarsy, D

RESUMO

Metoclopramide is an antiemetic drug which occasionally produced acute dystonic reactions. Although known to interfere with central dopamine mechanisms, it is frequently used in Parkinson's disease to prevent levodopa-induced nausea and vomiting. In this study metoclopramide did not increase Parkinsonism or reduce levodopa-induced involuntary movements in patients with Parkinson's disease. Pimozide, by contrast, increased Parkinsonism and reduced involuntary movements. The capacity of metoclopramide to produce acute dyskinesias while being apparently free of Parkinsonism effects is pharmacologically unique and differentiates this drug from the phenothiazines and butyrophenones.

Documentos Relacionados

• Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
• Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
• Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
• Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.
• Levodopa-induced dyskinesia and thalamotomy.